Potential for CAR T-Cell Therapy for R/R AML – OncLive
|
Potential for CAR T-Cell Therapy for R/R AML
OncLive WT-1 is an internal antigen, so it's not expressed on the cell surface. You can't really target it with a typical CAR against an antigen. So, there you have to actually do a TCR-transduced cell. We have some experience led by Aude Chapuis and Phil … |
